Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors

Abroad (travel likely)RecruitingPHASE3

Conditions

Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hunan Cancer Hospital, Changsha, Hunan, China
Contact: Study coordinator (Yongchang Zhang, MD) · zhangyongchang@csu.edu.cn · +86 731 89762323

Study leads

Yongchang Zhang, MD
Principal Investigator
Hunan Cancer Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC

Non Small Cell Lung Cancer Metastatic

Abroad (travel likely)RecruitingPHASE3

Viedma, Argentina

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Non-Squamous Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2, PHASE3

Tianjin, China · Hangzhou, China

First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Stage IV · Non-small Cell Lung Cancer Recurrent

Abroad (travel likely)RecruitingPHASE1, PHASE2

St Louis, United States

Label-free Femtosecond Laser Imaging Combined With the Fast Lung Artificial Intelligence Model for Rapid Intraoperative Diagnosis of Lung Surgical Specimens: A Multicentre, Prospective, Parallel-workflow, Non-inferiority Study.

Lung Cancer

Abroad (travel likely)Recruiting

Shanghai, China · Shanghai, China